Improvements in ADC Efficacy and Stability Through Proprietary Hydrophilic Linker Platform

SoluFlex LinkTM, enabling the next generation of ADC therapeutics

This white paper introduces SoluFlex Link™, a hydrophilic linker technology designed by LOTTE Biologics to address key challenges in antibody-drug conjugate (ADC) development.

Linker design plays a critical role in determining the stability, solubility, and overall therapeutic index of ADCs. Conventional linker approaches, however, can present limitations that impact both developability and clinical performance.
In this context, SoluFlex Link™ is explored as a potential approach to improving these parameters-supporting more stable conjugation, enhanced pharmacokinetics, and more consistent manufacturing outcomes.

For full access to this content, please click the document download button in the top right corner.